Piper Sandler Starts Tvardi Therapeutics Inc (TVRD) at Overweight

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Tvardi Therapeutics Inc (NASDAQ: TVRD) with a Overweight rating and a price target of $78.00.

The analyst comments: "We are initiating coverage on Tvard Therapeutics with an OW rating and $78 PT. With this, TVRD may be new to investors with its recent completion of a reverse merger with Cara Therapeutics and ~$46.1M proforma cash with runway into 2H26. Importantly, TVRD's lead asset, TTI-101 is being assessed in Ph2 REVERT-IPF with 4Q25 data and we believe it is positioned to drive broad improvement with an optimal profile. Specifically, TTI-101 is a differentiated STAT3 inhibitor small molecule with non-covalent bonding uniquely positioning it to specifically target canonical nuclear function with no mitochondrial effect. Hence, it has direct anti-fibrotic benefit across intrinsic (cellular) and extrinsic (immune) pathways with high PoS in IPF. Thus, we are initiating on TVRD ahead of this key de-risked catalyst and find it the perfect time to own with a next-generation asset also in development."

For an analyst ratings summary and ratings history on Tvardi Therapeutics Inc click here. For more ratings news on Tvardi Therapeutics Inc click here.

Shares of Tvardi Therapeutics Inc closed at $26.22 yesterday.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• AI/ML Innovations plans $2M private placement on the CSE
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027